Navigation Links
Yongye Biotechnology to Present at Roth Capital 'China Comes to Vegas' Conference
Date:11/10/2008

BEIJING, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that the Company will present at the upcoming Roth Capital "China Comes to Vegas" conference held on November 19-21, 2008 at the Wynn Hotel in Las Vegas, Nevada.

The Roth Capital "China Comes to Vegas" conference is a three day event dedicated to US listed companies with operations in China. There will be executives from more than 70 companies at the conference. Details of Yongye's presentation are:

Date: Friday, November 21, 2008

Time: 01:00 P.M. Pacific Time

Presenters: Mr. Zishen Wu, Chairman and CEO;

Mr. Larry Gilmore, Vice President of Corporate Strategy

Venue: Palmer 1

Wynn Hotel

Las Vegas, Nevada

The Company will be available to meet with analysts and investors during the conference. Participation in the Roth "China Comes to Vegas" conference is by invitation only. For more information about the conference, please visit http://www.roth.com/ or E-mail conference@roth.com .

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the research and development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Phone: +86-8232-8866 x8880

Email: larry.gilmore@gmail.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgirasia.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
2. Yongye Biotechnology International Raises $9.4 Million in Private Placement
3. Yongye Biotechnology International Announces Second Quarter Results
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Retains CCG Investor Relations
6. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
7. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
8. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
9. InNexus Biotechnology Receives Patent Grants in Europe
10. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
11. TechConnect World 2009 Matches Tomorrows Technology Solutions with Todays Business Needs for Clean-Technology, Biotechnology and Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):